Navigation Links
New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease
Date:6/11/2009

global Phase 3 clinical trials in adults, with regulatory submissions expected in 2010.

Pneumococcal Disease

Pneumococcal disease is complex and describes a group of illnesses, all caused by the bacterium Streptococcus pneumoniae. Pneumococcal disease affects both children and adults, and includes invasive infections such as bacteremia/sepsis and meningitis, as well as pneumonia and otitis media (middle ear infection).

Most recently serotype 19A, which is included in the candidate vaccine, has been increasing in prevalence in many regions of the world and is frequently resistant to antibiotics.

Indication for Prevenar

Prevenar is indicated for active immunization against disease by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (including sepsis, meningitis, pneumonia, bacteremia, and acute otitis media) in infants and children from 2 months up to 5 years of age.

Important Safety Information for Prevenar

In clinical studies (n=18,168), the most frequently reported adverse events included injection site reactions, fever (greater than or equal to 38 degrees C/100.4 degrees F), irritability, drowsiness, restless sleep, decreased appetite, vomiting, diarrhea, and rash.

Risks are associated with all vaccines, including Prevenar. Hypersensitivity to any vaccine component, including diphtheria toxoid, is a contraindication to its use. Prevenar does not provide 100% protection against vaccine serotypes or protect against non vaccine serotypes. The decision to administer Prevenar should be based on its efficacy in preventing invasive pneumococcal disease (IPD).

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervou
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... and Chinese Stem Cell Industry Report, 2014-2017" report ... undifferentiated biological cells that can differentiate into specialized cells ... cells. Stem cell therapy can be applied to treatment ... disease), nervous system diseases, damage or lesion of liver, ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) ... to their offering. The global companion ... of 22.7% from 2014 to 2019. Factors such as ... adoption of companion diagnostics by the pharmaceutical industry, support ...
(Date:9/18/2014)... DIEGO , Sept. 18, 2014  MEI Pharma, Inc. ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at BioCentury,s NewsMakers in the ... 8:30 a.m. Eastern time from the Millennium Broadway Hotel & ... live webcast of the presentation can be accessed at ...
(Date:9/18/2014)... , Pennsylvanie, 18 septembre 2014 /PRNewswire/ ... en 1974, a été depuis ... compléter les évaluations cliniques traditionnelles par des ... Outcomes) et sur les impacts économiques des ... A cours d,une ...
Breaking Biology Technology:Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 31974 - 2014 - Mapi fĂȘte ses 40 ans 2
... 2011 United Therapeutics Corporation (NASDAQ: UTHR ... quarter 2011 financial results before market open on Thursday, ... a half-hour teleconference on Thursday, July 28, 2011, at ... dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast ...
... N.C. Researchers at Duke University Medical Center have ... Chlamydia , the bacteria responsible for the largest ... The team, which included Duke University microbiologists ... bacteria,s self-defense mechanisms. The therapies that could ...
... RICHMOND, Calif., July 20, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... release its second quarter 2011 financial results on Wednesday, July ... be followed by a conference call at 5:00 p.m. ET, ... webcast. During the conference call, the company will review the ...
Cached Biology Technology:Newly designed molecule blocks chlamydia bacteria 2Newly designed molecule blocks chlamydia bacteria 3Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast 2
(Date:9/18/2014)... tiny strands of nucleic acid that contain instructions for ... data, our DNA is copied into RNA molecules, which ... in our cells. , Several years ago, scientists ... other known RNAs, this molecule is circular, and was ... has been known about how they are produced. Moreover, ...
(Date:9/18/2014)... from several disciplines will be celebrated tonight at the ... in improving the health of premature infants and in ... The researchers, whose work was supported by the National ... former Atomic Energy Commission, will be honored at a ... A bipartisan group of Members of Congress will be ...
(Date:9/18/2014)... the ideal animal in which to study the genes ... into tens of thousands of freshwater streams and lakes ... adapt to the new environment. , Breeding studies between ... up one of the genes that controls tooth number, ... regulation in a freshwater population is associated with a ...
Breaking Biology News(10 mins):Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 23rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3
... by a discovery about how chickens regulate their appetites. ... the signals sent from its stomach to its brain that ... Poultry farmers often have to restrict food for chickens ... can overeat, affecting their ability to reproduce. The ...
... has shown that obesity runs in families, and twin studies ... heritability estimates over 50%. 32 genes have been identified as ... genes alone cannot fully explain the high level of heritability ... individual differences in childhood body weight. This has led to ...
... to convention, vegetation, when well-maintained, can lower the rates ... robbery and burglary, in cities, according to a Temple ... Evidence from Philadelphia, PA," published in the journal, ... longstanding principle, particularly in urban planning, that you don,t ...
Cached Biology News:Appetite genes are key to better diets for poultry, study shows 2Study finds strong genetic component to childhood obesity 2Urban vegetation deters crime in Philadelphia 2
... The first SpeedVac to have active, ... Explorer SpeedVac System is the worlds first, ... components can be stacked together to form ... valuable benchspace. It is also the first ...
... RC Standard Bio for vacuum concentrator/centrifugal ... molecular biology and biochemistry for rapid and ... systems can be expanded with pumps, different ... of rotors (eliminating sample loss by transfer), ...
... dedicated concentrator for efficient drying of small ... integrated system combines the SpeedVac™ Concentrator and ... automatic pump and rotor control, and dual ... heater time), makes the DNA120 indispensable in ...
... MB (For small quantities of solvents with ... vacuum concentrator/centrifugal evaporator systems respond to specific ... rapid and safe concentration of heat-labile samples. ... pumps, different of cold traps and a ...
Biology Products: